US4412986A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Nifedipine-containing solid preparation composition
Assignee: Bayer AG
•
Filing: 1981-04-16
•
Granted: 1983-11-01
•
Expires: 2001-04-16
Abstract
Abstract A novel nifedipine-containing solid pharmaceutical preparation composition comprising a mixture of nifedipine and at least one 1st(a) substance selected from polyvinyl pyrrolidone, methyl cellulose, hydroxypropyl cellulose and hydroxypropylmethyl cellulose; a mixture of nifedipine, at least one 1st(b) substance selected from polyvinyl pyrrolidone, urea, citric acid mannitol, succinic acid, methyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose and amino acid, and at least one 2nd substance selected from a surface active agent, polyethylene glycol, propylene glycol, glycerol, a glycerol fatty acid ester and a vegetable oil; or a mixture of nifedipine, the 1st(b) substance, the 2nd substance and calcium lactate. The composition of this invention can increase the bioavailability of nifedipine and makes it possible to provide a nifedipine-containing pharmaceutical preparation which has small bulk and can be easily administered.
Inventors
- 👤 Hiroitsu Kawata
- 👤 Tadayoshi Ohmura
- 👤 Katsuhiko Yano
- 👤 Mikio Matsumura
- 👤 Saburo Higuchi
- 👤 Yoshiaki Soeishi
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 05:40
CPC Classifications
A; A61; A61K; A61K47/00; A61K47/30; A61K47/36; A61K47/38; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/44; A61K47/32; A61K9/00; A61K9/14; A61K9/141; A61K9/145; A61K9/146; A61K9/20; A61K9/2004
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
33 words
A nifedipine-containing solid composition comprising a coprecipitate (a) of nifedipine and (b) about 1 to 20 times its weight of a member selected from the group consisting of polyvinylpyrrolidone, methylcellulose, hydroxypropylcellulose and hydroxypropylmethylcellulose.
Claim 2
Dependent Claim
33 words
A nifedipine-containing solid composition comprising a coprecipitate (a) of nifedipine and (b) about 1 to 20 times its weight of a member selected from the group consisting of polyvinylpyrrolidone, methylcellulose, hydroxypropylcellulose and hydroxypropylmethylcellulose.
Claim 3
Dependent Claim
20 words
A composition according to claim 1, wherein (b) is present in about 1 to 10 times the weight of (a).
Claim 4
Dependent Claim
10 words
A composition according to claim 1, wherein (b) is polyvinylpyrrolidone.
Claim 5
Dependent Claim
10 words
A composition according to claim 1, wherein (b) is methylcellulose.
Claim 6
Dependent Claim
10 words
A composition according to claim 1, wherein (b) is hydroxypropylcellulose.
Claim 7
Dependent Claim
10 words
A composition according to claim 1, wherein (b) is hydroxypropylmethylcellulose.
Claim 8
Dependent Claim
55 words
A composition according to claim 1, further containing (c) about 0.1 to 10 parts per part by weight of (a) of at least one compound selected from the group consisting of an anionic surface active agent, a nonionic surface active agent, polyethylene glycol, propylene glycol, glycerol, a glycerol fatty acid ester and a vegetable oil.
Claim 9
Dependent Claim
12 words
A composition according to claim 7, wherein (c) is sodium lauryl sulfate.
Claim 10
Dependent Claim
11 words
A composition according to claim 7, wherein (c) is polyethylene glycol.
Claim 11
Dependent Claim
36 words
A composition according to claim 1, further containing (d) about 0.1 to 10 parts per part by weight of (a) of at least one member selected from the group consisting of aluminum silicate and calcium lactate.
Claim 12
Dependent Claim
29 words
A method of effecting coronary vascular dilation with high bioavailability in humans and animals which comprises orally administering a therapeutically effective amount of the composition claimed in claim 1.
Claim 13
Dependent Claim
29 words
A method of effecting coronary vascular dilation with high bioavailability in humans and animals which comprises orally administering a therapeutically effective amount of the composition claimed in claim 7.
Claim 14
Dependent Claim
29 words
A method of effecting coronary vascular dilation with high bioavailability in humans and animals which comprises orally administering a therapeutically effective amount of the composition claimed in claim 11.
Claim 15
Dependent Claim
17 words
A composition according to claim 1 in the form of a tablet of less than 400 mg.
Claim 16
Dependent Claim
17 words
A composition according to claim 1 in the form of a tablet of less than 250 mg.
References Cited (Backward Citations)
US3862161A
Cited
US3799934A
Cited
US3932645A
Cited
US3784684A
Cited
US3920823A
Cited
US3959296A
Cited
US3943140A
Cited
US3971796A
Cited
GB1456618A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-10-31 | 1987-05-02 | 1987-11-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-10-31 | 1991-05-02 | 1991-11-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-10-31 | 1995-05-02 | 1995-11-01 | $7700.00 | Window Closed / Lapsed |